AbbVie (ABBV)

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.03% on an annualized basis producing an average annual return of 16.59%. Currently, AbbVie has a market capitalization of $442.79 billion.

AbbVie knows how to plan ahead.

AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.

In the past five years, this top healthcare stock has risen by close to 130%.

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...

AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics.

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 4.21% on an annualized basis producing an average annual return of 15.79%. Currently, AbbVie has a market capitalization of $417.60 billion.

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...

These healthcare stocks may be the building blocks of a winning portfolio.

An intriguing acquisition could bring exciting new drugs into the medicine maker's development pipeline.

The company is already renowned by many as a giant in the segment.

Get rich slowly. How? Hold these stocks and reinvest the dividends they pay.

Don't wait too long to get in on these outstanding dividend payers.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Now's the time to load up on these high-yielders.

Driving revenue growth and earnings growth are two different things.

New cancer therapies may help fund dividend growth.

For a solid yield and strong upside potential, this pharmaceutical stock is worth considering.

The market is underestimating these companies' long-term prospects.

The most recent research report on the "Dry eye syndrome drugs Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic foreca

Wall Street analysts expect market-beating returns from healthcare and communication services stocks over the next year.